Glioblastoma Multiforme (GBM)

CBD has the potential to influence many of the key pathways involved in Glioblastoma pathogenesis, from tumor stemness and proliferation to angiogenesis and local invasion. Glioblastoma tumors express CB2 receptors, through which CBD and other cannabinoids are thought to exert their anti-cancer efforts (Ellert-Miklaszewska, Adv Exp Med Biol, 2013). Developing clinical trials to evaluate CBD combination therapies’ efficacy may represent an important next step toward improving the standard of care for treating glioblastoma for a population of patients with few effective therapeutic options available.